Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293423 · ClinicalTrials.gov registry record · Phase 1
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00293423 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 96 participants.
The verdict
NCT00293423, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
Vaccines made from a person's tumor cells, such as gp96 heat shock protein-peptide complex, may help the body build an effective immune response to kill tumor cells. This phase I/II trial is studying the side effects and best dose of gp96 heat shock protein-peptide complex vaccine to see how well it works in treating patients with recurrent or progressive high-grade glioma over time.
Interventions
- BIOLOGICAL HSPPC-96
- PROCEDURE Standard Surgical Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2005-11-18 |
| Est. Completion | 2013-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293423
The ClinicalTrials.gov registry entry for NCT00293423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HSPPC-96 is the first listed.
NCT00293423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293423 about?
NCT00293423 is a clinical study titled "GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma". Vaccines made from a person's tumor cells, such as gp96 heat shock protein-peptide complex, may help the body build an effective immune response to kill tumor cells. This phase I/II trial is studying the side effects and best dose of gp96 heat shock protein-peptide complex vaccine to see how well it...
What is the current status of trial NCT00293423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2005-11-18. Estimated completion is 2013-01-12.
What interventions are being tested in trial NCT00293423?
The interventions under investigation include: HSPPC-96 (BIOLOGICAL), Standard Surgical Resection (PROCEDURE).
Who is sponsoring clinical trial NCT00293423?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.